SVVYGLR 是一种骨桥蛋白衍生肽,能够促进成纤维细胞分化为肌成纤维细胞样细胞、促进心肌成纤维细胞产生 III 型胶原蛋白、在体外激活内皮细胞的黏附、迁移及管形成、促进血管形成和伤口愈合以及促进真皮成纤维细胞和角质形成细胞的迁移,可用于血管生成、真皮伤口和骨再生相关研究。
产品编号: MS-C29443 CAS No.: 292851-89-9 分子式: C36H60N10O10 分子量: 792.92
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SVVYGLR 是一种骨桥蛋白衍生肽,能够促进成纤维细胞分化为肌成纤维细胞样细胞、促进心肌成纤维细胞产生 III 型胶原蛋白、在体外激活内皮细胞的黏附、迁移及管形成、促进血管形成和伤口愈合以及促进真皮成纤维细胞和角质形成细胞的迁移,可用于血管生成、真皮伤口和骨再生相关研究。

生物实验数据

生物活性 SVVYGLR is an osteopontin-derived peptide that promotes the differentiation of fibroblasts into myofibroblast-like cells, promotes the production of type III collagen by cardiac fibroblasts, activates endothelial cell adhesion, migration, and tube formation in vitro, promotes angiogenesis and wound healing, and promotes the migration of dermal fibroblasts and keratinocytes, and can be used in research related to angiogenesis, dermal wounds, and bone regeneration.
体外研究
(In Vitro)

SVVYGLR (0.02 μg/mL) 可在体外激活内皮细胞的黏附、迁移和成管作用。
SVVYGLR (0.01-100 μg/mL;包被 2 小时,细胞孵育 30 分钟) 可呈浓度依赖性增强 hMSCs、hPLFs、hGFs 和 HUVECs 的黏附能力,在 100 μg/mL 时作用最强。
SVVYGLR (1-1000 ng/mL;每 2 天更换培养基持续培养,于第 6 天检测) 可呈浓度依赖性促进 hMSCs、HUVECs 和 hPLFs 的增殖 (对 hGFs 无此作用),在第 6 天 100 ng/mL 浓度下效果最强。
SVVYGLR (10-1000 ng/mL;RAW264.7 细胞处理 5 天,BMMs 处理 10 天) 可抑制 RAW264.7 细胞和 BMMs 中的破骨细胞生成,在 100 ng/mL 浓度下抑制作用显著。
SVVYGLR (100 ng/mL;作用 24、72、96 h) 可在 100 ng/mL 浓度下抑制 RANKL 诱导的 pNFAT/Luc-RAW264.7 细胞中 NFAT 的活性。
SVVYGLR (100 ng/mL;作用 3、5 天) 可在 RANKL 刺激的 RAW264.7 细胞中以 100 ng/mL 的浓度下调破骨细胞生成标记基因 (降钙素受体、组织蛋白酶 K、TRAP) 及整合素 α9 的表达。
SVVYGLR (10 ng/mL;36 h) 可在 36 h 时显著促进大鼠真皮成纤维细胞 (RDFs) 向划痕创面区域迁移。
SVVYGLR (10 ng/mL; 10 h) 可在 10 小时时显著促进人表皮角质形成细胞 (HEKa) 向划痕损伤区域迁移。
SVVYGLR (10 ng/mL;3 h) 在 3 小时的趋化小室迁移实验中显著增强大鼠真皮成纤维细胞 (RDFs) 和人上皮角质形成细胞 (HEKa) 的迁移活性。

Cell Proliferation Assay

Cell Line: hMSCs, hPLFs, hGFs, HUVECs
Concentration: 1-1000 ng/mL
Incubation Time: 6 days
Result: Enhanced proliferation of hMSCs 1.4-fold, HUVECs 1.2-fold, and hPLFs 1.1-fold at 100 ng/ml on day 6 in a concentration-dependent manner. Did not affect hGF proliferation.

RT-PCR

Cell Line: RAW264.7 cells
Concentration: 100 ng/mL
Incubation Time: 3, 5 days
Result: Decreased mRNA expression of calcitonin receptor, cathepsin K, TRAP, and integrin α9 in RANKL-stimulated cells relative to RANKL-only controls.

Cell Migration Assay

Cell Line: Rat dermal fibroblasts (RDFs)
Concentration: 10 ng/mL
Incubation Time: 0, 12, 24, 36 h
Result: Significantly accelerated migration into the scratch wound area at 36 h compared with untreated controls and scrambled SV peptide (rSV)-treated groups.

Cell Migration Assay

Cell Line: Human epithelial keratinocytes (HEKa)
Concentration: 10 ng/mL
Incubation Time: 0, 5, 10 h
Result: Significantly accelerated migration into the scratch wound area at 10 h compared with untreated controls and rSV-treated groups.

Cell Migration Assay

Cell Line: Rat dermal fibroblasts (RDFs) and Human epithelial keratinocytes (HEKa)
Concentration: 10 ng/mL
Incubation Time: 3 h
Result: Significantly enhanced migratory activity compared with untreated controls and rSV-treated groups.

Cell Proliferation Assay

Cell Line: Rat dermal fibroblasts (RDFs) and human epithelial keratinocytes (HEKa)
Concentration: 10 ng/mL
Incubation Time: 24, 48, 72, 96 h
Result: Showed no significant differences in proliferation compared with rSV-treated and untreated controls over 24-96 h.
体内研究
(In Vivo)

SVVYGLR (0.02 µg/mL;通过扩散室植入;持续 5 天) 在背部气囊模型中可显著诱导小鼠体内血管生成,平均血管生成分级为 2.00。
SVVYGLR (10 µg;通过胶原海绵植入;缺损创建时单次给药) 可在大鼠颅骨缺损模型中于 3 周时抑制骨缺损部位的破骨细胞数量,并在 5 周时促进胶原海绵吸收及致密骨形成。
SVVYGLR (12.5 μg/gel;以 Medgel 载体经局部给药;伤口形成时单次给药) 在大鼠中通过刺激成纤维细胞迁移、成纤维细胞向肌成纤维细胞分化及血管生成来促进皮肤伤口愈合。

Animal Model: BALB/cAnNCrj (6-week-old female)
Dosage: 0.02 µg/mL
Administration: Implanted via diffusion chamber; 5 days
Result: Achieved a mean angiogenesis grade of 2.00; induced spiral and immature blood vessels; reached an angiogenic level approximately the same as that of vascular endothelial growth factor (VEGF).
Animal Model: Sprague-Dawley (male, 12-week-old, artificial bone defect model)
Dosage: 10 µg
Administration: implanted via collagen sponge; single administration at the time of defect creation
Result: Reduced number of TRAP-positive osteoclasts in bone defect area significantly compared to controls at 3 weeks post-operation; Decreased area of remaining collagen sponge significantly compared to controls at 5 weeks post-operation; Induced new bone formation extending to the periosteal surface (with compact bone morphology and cement lines) surrounding the sponge graft at 5 weeks post-operation。
Animal Model: Sprague-Dawley (male, 8-week-old, full-thickness 5-mm skin wound model)
Dosage: 12.5 μg/gel
Administration: topical via Medgel; single application at wound creation
Result: Accelerated wound closure compared to control and PBS groups (significant at days 6 and 8); Increased migration of HSP-47-positive fibroblasts to the wound area at day 4; Significantly enhanced number of α-SMA-positive myofibroblasts in the wound area at day 14; Marked increase in von Willebrand factor-positive neomicrovessels at day 7.

化学信息

分子量 792.92
分子式 C36H60N10O10
CAS No. 292851-89-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础